tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Teva sees FY24 adjusted EBITDA $4.7B-$5B

Sees FY24 capital expenditures $500M. Sees FY24 free cash flow $1.7B-$2B. Says on track for FY27 targets. Guidance taken from Q3 earnings conference call.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1